CoChat
Sign Up
Cited by 99

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Activation of the Enhancer of Zeste Homologue 2 Gene by the Human Papillomavirus E7 Oncoprotein

Holland, Daniela, Hoppe-Seyler, Karin, Schuller, Bettina, Lohrey, Claudia, Maroldt, Julia, Dürst, Matthias, Hoppe-Seyler, Felix·2008·Cancer Research
DOI 10.1158/0008-5472.can-08-1134
Open this paper in CoChat — free account

Abstract

The malignant phenotype of human papillomavirus (HPV)-positive cancer cells is maintained by the activity of the viral E6 and E7 genes. Here, we identified the polycomb group gene enhancer of zeste homologue 2 (EZH2) as a novel downstream target for the viral oncogenes in HPV-transformed cells. EZH2 expression was activated by HPV16 E7 at the transcriptional level via E7-mediated release of E2F from pocket proteins. RNA interference analyses showed that continuous EZH2 expression is required for the proliferation of HPV-positive tumor cells by stimulating cell cycle progression at the G1-S boundary. In addition to its growth-promoting activity, EZH2 also contributed to the apoptotic resistance of cervical cancer cells. Furthermore, we found that HPV-positive dysplastic and tumorigenic cervical lesions were characterized by high levels of EZH2 protein in vivo. We conclude that the E7 target gene EZH2 is a major determinant for the proliferation of HPV-positive cancer cells and contributes to their apoptotic resistance. Moreover, EZH2 may serve as a novel therapeutic target for the treatment of cervical cancer. [Cancer Res 2008;68(23):9964–72]

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-08-1134

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 37

  1. Münger K, Basile JR, Duensing S, et al. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001; 20: 7888–98. · DOI
  2. Duensing S, Münger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer 2004; 109: 157–62. · DOI
  3. Mantovani F, Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2001; 20: 7874–87. · DOI
  4. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996; 380: 79–82. · DOI · Paper page
  5. Kuner R, Vogt M, Sültmann H, et al. Identification of cellular targets for the human papillomavirus E6 and E7 oncogenes by RNA interference and transcriptome analyses. J Mol Med 2007; 85: 1253–62. · DOI
  6. Czermin B, Melfi R, McCabe D, Seitz V, Imhof A, Pirrotta V. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell 2002; 111: 185–96. · DOI
  7. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev 2002; 16: 2893–905. · DOI · Paper page
  8. Jacobs JJ, van Lohuizen M. Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochim Biophys Acta 2002; 1602: 151–61. · DOI
  9. Visser HP, Gunster MJ, Kluin-Nelemans HC, et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 2001; 112: 950–8. · DOI
  10. Croonquist PA, Van Ness B. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 2005; 24: 6269–80. · DOI
  11. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 2004; 23: 5759–69. · DOI
  12. Yu J, Cao Q, Mehra R, et al. Integrative genomics analysis reveals silencing of β-adrenergic signaling by polycomb in prostate cancer. Cell 2007; 12: 419–31. · DOI
  13. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003; 22: 5938–45. · DOI · Paper page
  14. Vogt M, Butz K, Dymalla S, Semzow J, Hoppe-Seyler F. Inhibition of Bax activity is crucial for the antiapoptotic function of the human papillomavirus E6 oncoprotein. Oncogene 2006; 25: 4009–15. · DOI · Paper page
  15. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 19: 550–3. · DOI
  16. Baldwin A, Huh K-W, Münger K. Human papillomavirus E7 oncoprotein dysregulated steroid receptor coactivator 1 localization and function. J Virol 2006; 80: 6669–77. · DOI
  17. Huh K-W, DeMasi J, Ogawa H, Nakatani Y, Howley PM, Münger K. Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600. Proc Natl Acad Sci U S A 2005; 102: 11492–7. · DOI · Paper page
  18. Butz K, Geisen C, Ullmann A, Zentgraf H, Hoppe-Seyler F. Uncoupling of p21WAF1/CIP1/SDI1 mRNA and protein expression upon genotoxic stress. Oncogene 1998; 17: 781–7. · DOI
  19. Fox MH. A model for the computer analysis of synchronous DNA distributions obtained by flow cytometry. Cytometry 1980; 1: 71–7. · DOI
  20. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995; 92: 9363–7. · DOI · Paper page
  21. Häfner N, Driesch C, Gajda M, et al. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 2008; 27: 1610–7. · DOI
  22. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–25. · DOI · Paper page
  23. Hiraiwa A, Kiyono T, Suzuki S, Ohashi M, Ishibashi M. E7 proteins of four groups of human papillomaviruses, irrespective of their tropism or cancer association, possess the ability to transcativate transcriptional promoters E2F site dependently. Virus Genes 1996; 12: 27–35. · DOI
  24. Armstrong DJ, Roman A. The relative ability of human papillomavirus type 6 and human papillomavirus type 16 E7 proteins to transactivate E2F-responsive elements is promoter- and cell-dependent. Virology 1997; 239: 238–46. · DOI
  25. Chong AS, Finnegan A, Jiang X, et al. Leflunomide, a novel immunosuppressive agent. The mechanism of inhibition of T cell proliferation. Transplantation 1993; 55: 1361–6. · DOI
  26. Linke SP, Clarkin KC, Di Leonardo A, Tsou A, Wahl GM. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 1996; 10: 934–47. · DOI
  27. Wells SI, Francis DA, Karpova AY, Dowhanick JJ, Benson JD, Howley PM. Papillomavirus E2 induces senescence in HPV-positive cells via pRb- and p21CIP-dependent pathways. EMBO J 2000; 19: 5762–71. · DOI
  28. Hall AH, Alexander KA. RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J Virol 2003; 77: 6066–9. · DOI
  29. Bulk S, Berkhof J, Bulkmans NWJ, et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer 2006; 94: 171–5. · DOI
  30. Shi B, Liang J, Yang X, et al. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol 2007; 27: 5105–19. · DOI
  31. Kotake Y, Cao R, Viatour P, Sage J, Zhang Y, Xiong Y. pRB family proteins are required for H3K27 trimethylation and polycomb repression complexes binding to and silencing p16INK4α tumor suppressor gene. Genes Dev 2007; 21: 49–54. · DOI
  32. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129–36. · DOI · Paper page
  33. Wagener N, Holland D, Bulkescher J, et al. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Int J Cancer 2008; 123: 1545–50. · DOI
  34. Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006; 5: 1886–901. · DOI
  35. Payne S, Kernohan NM, Walker F. Proliferation in the normal cervix and in preinvasive cervical lesions. J Clin Pathol 1996; 49: 667–71. · DOI
  36. Ding L, Erdmann C, Chinnaiyan AM, Merajver SD, Kleer CG. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res 2006; 66: 4095–9. · DOI
  37. Takeshita F, Minakuchi Y, Nagahara S, et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A 2005; 102: 12177–82. · DOI

Cited by

See all 99

Metadata

Authors
Holland, D., Hoppe-Seyler, K., Schuller, B., Lohrey, C., Maroldt, J., Dürst, M., & Hoppe-Seyler, F.
Affiliations
  • 1Molecular Therapy of Virus-Associated Cancers (F065), German Cancer Research Center, Heidelberg, Germany and
  • 2Gynäkologische Molekularbiologie, Frauenklinik der FSU Jena, Jena, Germany
Venue
Cancer Research
Publisher
American Association for Cancer Research (AACR)
Published
2008-12-01
Volume
68
Issue
23
Pages
9964-9972
ISSN
  • 0008-5472
  • 1538-7445
DOI
10.1158/0008-5472.can-08-1134
Cited by
99
References
7
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review